Abstract
Background: Somatostatin analogues are frequently used for medical treatment of acromegaly. The rationale for their use is based on the inhibition of pituitary GH secretion; however, there is in vitro evidence that octreotide also acts to inhibit hepatic IGF1 generation. Aim & design: We studied the pituitary-independent effects of octreotide on IGF1 generation in 11 severely GH-deficient (GHD) humans (age 38, range 23-52; seven males; body mass index 24.7±3 kg/m2; peak-stimulated GH
Original language | English |
---|---|
Pages (from-to) | 543-548 |
Number of pages | 5 |
Journal | European Journal of Endocrinology |
Volume | 160 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2009 |